Two analyst calls on AST SpaceMobile reached opposite conclusions from the same vulnerability. Piper Sandler focused on schedule risk and cut the stock to neutral. Clear Street kept a buy rating, arguing that AST remained about six months ahead of SpaceX in direct-to-cell service and that the market was overlooking launch risks faced by both companies.
The disagreement is useful because it exposes the operational question beneath the price targets. AST currently uses SpaceX's Falcon 9 while also competing with SpaceX's direct-to-cell network. Clear Street pointed to Blue Origin's New Glenn as a possible alternative, with capacity for more BlueBird satellites per flight than Falcon 9 according to the original report.
Alternative launch agreements are valuable only if the rockets are available, certified for the payload and able to meet the required cadence. A theoretical capacity advantage does not guarantee a launch date. AST's second-quarter disclosure said it had agreements with multiple providers and targeted roughly 45 satellites in orbit by early 2027. That target had previously been set for the end of 2026.
The company has nevertheless demonstrated real progress. Six BlueBird spacecraft reached orbit within 50 days, lifting the total to 13. BlueBirds 14, 15 and 16 were nearing shipment, while later satellites were in production or assembly. That manufacturing pipeline reduces one risk, but it does not remove the need for timely launches and successful commissioning.
Investors do not have to choose between the analysts' price targets to evaluate the thesis. They can track booked launch slots, satellites per mission, successful deployments and the movement of the early-2027 target. Clear Street's view is stronger if alternative vehicles provide reliable capacity and AST preserves its lead. Piper's caution is stronger if schedules slip again. The launch manifest will resolve that disagreement more reliably than a target price.
Each confirmed mission will narrow the range of possible outcomes.